



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiflabs.com Website : www.indswiflabs.com
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2024

Date: 11th November, 2024

The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

ISIN: INE915B01019
BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

SUB: OUTCOME OF BOARD MEETING

Dear Sir,

Pursuant to the provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter “SEBI Listing Regulations”) we wish to inform you that the Board of Directors of the Company in their meeting held today i.e. 11th November, 2024, have considered and inter-alia approved the following: -

1. Standalone and Consolidated Un-audited Financial Results of Ind-Swift Laboratories Limited for the quarter and half year ended 30th September, 2024. The Limited Review Report as submitted by the Statutory Auditors is also enclosed along with the Unaudited Financial Results.

The details required under SEBI Master Circular issued vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed herewith as Annexure I.

2. Reconstitution of the following Committees of the Board of Directors, effective from 12th November, 2024 –

COMMITTEE	MEMBER	DESIGNATION
1. Nomination and Remuneration Committee	Param Bir Singh	Chairman (Independent Director)
	S P Sharma	Member (Independent Director)
	Neerja Chathley	Member (Independent Director)
2. Stakeholders Relationship Committee	Param Bir Singh	Chairman (Independent Director)
	Navrattan Munjal	Member (Independent Director)
	S P Sharma	Member (Independent Director)
3. Sub- Committee	Navrattan Munjal	Chairman (Independent Director)
	Himanshu Jain	Member (Independent Director)
	Param Bir Singh	Member (Independent Director)
	S P Sharma	Member (Independent Director)





Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiflabs.com Website : www.indswiflabs.com
CIN No. L24232CH1995PLC015553



4. Compensation Committee	Rajinder Kumar Gupta	Chairman (Independent Director)
	Navrattan Munjal	Member (Independent Director)
	S P Sharma	Member (Independent Director)

The unaudited financial results of the Company will also be available on the website of the Company i.e. www.indswiflabs.com.

The Board Meeting commenced at 05:00 P.M and concluded at 06:45 P.M.

You are requested to kindly take the same on record.

Thanking you,
For **IND-SWIFT LABORATORIES LTD.**



PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY

Encl: As above



RATTAN KAUR & ASSOCIATES

CHARTERED ACCOUNTANTS

SCF: 1, SECTOR: 20-C

CHANDIGARH: 160020

Mobile: 9501343300

Email: carattan@gmail.com

LIMITED REVIEW

Independent Auditor's review Report on the Standalone Unaudited Financial Results of Ind-Swift Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

The Board of Directors
Ind-Swift Laboratories Ltd.
SCO 850, Shivalik Enclave
NAC Manimajra
Chandigarh

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Ind-Swift Laboratories Ltd. for the Quarter and half year ended 30.09.2024, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (the 'Listing Regulation').
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rattan Kaur & Associates
Chartered Accountants
(Regd No.:022513N)



Place: Chandigarh
Date: 11.11.2024
UDIN:24513530BKEFKD7288

Rattan Kaur
(Partner)
M. No. 513530



IND-SWIFT LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30th SEPT 2024						
CIN L24232CH1995PLC015553						
Rs. In Lakhs						
Particulars	STANDALONE					
	Quarter Ended 30.09.2024	Quarter Ended 30.06.2024	Quarter Ended 30.09.2023	Half Year Ended 30.09.2024	Half Year Ended 30.09.2023	Year Ended 31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income from Operations:						
Revenue from operations	270.62	3045.61	27029.99	3316.23	56930.55	122731.79
Other Income	1294.61	1113.94	739.73	2408.56	1294.99	4531.35
Total Income	1565.23	4159.55	27769.72	5724.78	58225.54	127263.15
EXPENSES:						
a. Cost of Materials Consumed	0.00	0.00	13277.12	0.00	27897.72	56117.61
b. Purchase of stock in Trade	49.85	2517.83	103.77	2567.68	237.62	2533.24
c. (Increase) /decrease in FG,WIP & stock in trade	0.00	0.00	(357.63)	0.00	253.75	3707.27
d. Employee benefit	521.74	555.67	3641.75	1077.41	7470.55	14888.43
e. Finance Costs	41.08	16.87	2113.77	57.95	4152.14	5109.55
f. Depreciation	21.65	24.99	1318.75	46.64	2707.29	5330.28
g. Other expenditure	898.92	425.41	4025.07	1324.33	8749.44	20488.66
TOTAL EXPENSES	1533.24	3540.78	24122.60	5074.01	51468.53	108175.05
Profit/(loss) before exceptional Items and Tax	31.99	618.77	3647.12	650.77	6757.01	19088.09
Exceptional Items (Income) /loss	0.00	0.00	0.00	0.00	0.00	(38659.00)
Profit/(loss) before Tax (After exceptional Items)	31.99	618.77	3647.12	650.77	6757.01	57747.09
Tax Expenses :-						
Current Tax	0.00	0.00	637.23	0.00	1180.58	16088.66
Mat credit Utilisation	0.00	0.00	0.00	0.00	861.52	897.50
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1084.34)
Income Tax Adjustment of Previous Years	0.00	0.00	0.34	0.00	0.34	6.25
Profit/ (Loss) after tax and before share of	31.99	618.77	3009.56	650.77	4714.57	41839.01
Share of profit (loss) in joint venture	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) for the period from continuing operations	31.99	618.77	3009.56	650.77	4714.57	41839.01
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit / (Loss) for the period after tax & Exceptional Items)	31.99	618.77	3009.56	650.77	4714.57	41839.01
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	0.00	37.48	0.00	37.48	34.70
Other Comprehensive Income (Loss) for the period , net of Tax	0.00	0.00	37.48	0.00	37.48	34.70
Total Comprehensive Income for the Period	31.99	618.77	2972.08	650.77	4677.09	41804.31
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						86315.53
EPS (of Rs. 10/- each) (Not annualised)						
Basic	0.05	1.05	5.09	1.10	7.98	70.81
Diluted	0.05	1.05	5.09	1.10	7.98	70.81

FOR IND SWIFT LABORATORIES LIMITED

N.R. Munjal

N.R. MUNJAL
CHAIRMAN & MANAGING DIRECTOR



PLACE: CHANDIGARH
DATE: 11/11/2024

Works : Barwala Road, Vill. Bhagwanpur, Near Dera Bassi, Distt. Mohali (Punjab)
Tel. : + + 91-1762-281072, Telefax : ++91-1762-281073



IND-SWIFT LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED
 Standalone Statement of Assets & Liabilities :

	Unaudited	Audited
	As At 30.09.2024	As At 31.03.2024
ASSETS		
Non-current assets :		
Property, Plant and Equipment	498.04	532.48
Right of Use - Land	-	-
Capital work-in progress	-	-
Investment property	227.61	229.91
Intangible assets under development	-	-
Financial Assets		
a) Investments		
- In subsidiaries and associates	8,055.25	8,055.25
- In Others	16,672.73	8,539.24
b) Other Non-current Financial Assets	46.25	41.05
Deferred tax assets (net)	3,183.88	3,183.88
Other non-current assets	36,971.93	35,343.03
TOTAL NON- CURRENT ASSETS	65,655.68	55,924.83
Current Assets		
Inventories	-	-
Financial Assets		
(a) Trade receivables	2,788.01	10,660.13
(b) Cash and cash equivalents	43,601.16	42,572.92
(c) Other current financial Assets	-	-
Other current assets	1,593.99	1,320.62
Total Current Assets	47,983.16	54,553.68
Grand total	1,13,638.85	1,10,478.51
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	5,908.69	5,908.69
(b) Other Equity	94,839.41	86,315.53
Total Equity	1,00,748.09	92,224.21
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	273.59	299.64
(b) Lease liabilities	-	-
Provisions	122.64	122.64
Other Non current Liabilities	-	-
Total Non-Current Liabilities	396.22	422.28
Current liabilities		
Financial Liabilities		
(a) Borrowings	519.33	531.83
(b) Lease liabilities	-	-
(c) Trade payables	1,516.18	6,391.05
(d) Other Financial Liabilities	-	-
(e) Current Provisions	10,088.66	10,088.66
Other current liabilities	370.37	820.47
Total Current Liabilities	12,494.53	17,832.02
Grand Total	1,13,638.85	1,10,478.51
	-0.00	0.00

PLACE: CHANDIGARH
 DATE: 11/11/2024

FOR IND SWIFT LABORATORIES LIMITED

N.R. MUNJAL
 CHAIRMAN & MANAGING DIRECTOR





Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiflabs.com Website : www.indswiflabs.com
CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED

STANDALONE

STANDALONE CASH FLOW STATEMENT FOR YEAR ENDED 30.09.2024

	Half Year ended 30.09.2024	Year ended 31.03.2024
Rs in Lacs		
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and Extra-Ordinary Items	650.77	19,088.10
ADJUSTMENTS FOR:		
i) Depreciation	46.64	5,330.27
ii) Provision For doubtful Debt	-	2,476.68
iii) Exchange (profit)/loss	-	(249.79)
iv) Interest on Term loans, NCDS & FD	-	4,510.64
v) Interest received	(3,288.35)	(1,837.14)
vi) Loss/(Profit) on sale of fixed assets	-	2,253.20
vii) Income tax adj of previous years	-	(6.25)
viii) Amortisation of Subsidy	-	(1.27)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	(2,590.94)	31,564.44
ADJUSTMENTS FOR:		
i) Trade & Other Receivables	7,872.12	(10,439.11)
ii) Inventories	-	3,228.50
iii) Other assets	(1,907.48)	(43,543.59)
iv) Current Liabilities	(5,324.98)	527.09
v) Working Capital Borrowing	8.69	685.87
Net Cash flow from operating Activities	(1,942.60)	(17,976.80)
B. CASH FLOW FROM INVESTING ACTIVITIES		
i) Purchase of fixed Assets Tangible	(9.90)	(4,451.68)
ii) Sale of fixed assets	-	294.65
iii) (Purchase)/ Sale of Investments	(8,133.49)	(8,112.00)
iv) Interest Received	3,288.35	1,837.14
Net Cash from investing activities	(4,855.04)	(10,431.88)
C. CASH FLOW FROM FINANCING ACTIVITIES		
i) Repayment of Term Loans to Banks & Financial Institutions & FD	(29.50)	(3,742.78)
ii) Interest paid on Term Loans & FD	(17.74)	(12,604.55)
iii) Cash flow from Slump sales net of Assets/liab transferred	-	93,520.59
iv) Payment of Income Tax	0.00	(7,187.35)
v) Proceeds from Fully Convertible Warrants	7,873.12	
Net Cash flow from Financing Activities	7,825.88	69,985.91
Net increase in Cash or Cash Equivalents	1,028.24	41,577.22
Opening Cash & Cash Equivalents	42,572.92	995.71
Closing Cash & Cash Equivalents	43,601.16	42,572.93
Closing Cash & Cash Equivalents	43,601.16	42,572.93

DATE: 11/11/2024
PLACE: CHANDIGARH

FOR IND SWIFT LABORATORIES LIMITED


N.R. MUNJAL
CHAIRMAN & MANAGING DIRECTOR





RATTAN KAUR & ASSOCIATES

CHARTERED ACCOUNTANTS

SCF: 1, SECTOR: 20-C

CHANDIGARH: 160020

Mobile: 9501343300

Email: carattan@gmail.com

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and year to date results of Ind-Swift Laboratories Ltd. pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, (as amended).

The Board of Directors
Ind-Swift Laboratories Ltd.
SCO 850, Shivalik Enclave
NAC Manimajra
Chandigarh

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ("the Statement") of **IND-SWIFT LABORATORIES LIMITED** (the "Holding Company"), its subsidiaries (the Holding company and its subsidiaries together referred to as "the Group") for the quarter & half year ended 30th September, 2024 and the consolidated year to date results for the period 01st April 2024 to 30th September 2024, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations").
- 2) This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matter, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular No. CIR/CFD/CMD1/44/2019 date March 29, 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4) The Statement includes the results of:

Particulars	Name
Subsidiary Companies	Ind Swift Laboratories Inc. USA Fortune (India) Constructions Ltd MJM Remedies Private Limited ISLL Middle East LLC-FZ
Joint Venture	INDIS Healthcare LLP

- 5) Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6) The consolidated unaudited financial results includes the interim financial statements/financial information/financial results of three subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/financial information/financial results reflect total revenue of Rs 930.97 Lakhs and Rs.1202.02 Lakhs for quarter ended 30.09.2024 and half yearly ended 30.09.2024 respectively, total net profit before tax of Rs 26.37 Lakhs and Rs. 494.41 Lakhs for quarter ended 30.09.2024 and half yearly ended 30.09.2024 respectively and total comprehensive income of Rs 9.35 Lakhs and Rs.515.88 Lakhs for the quarter ended 30.09.2024 and half yearly ended 30.09.2024 respectively as considered in the consolidated unaudited financial results.
- 7) The consolidated unaudited financial results include the interim financial statements/Financial information/Financial results of INDIS healthcare LLP (Joint Venture) which have been reviewed/audited by the auditors whose interim Financial = statements/Financial information/Financial results reflect total Net Profit/(Loss) of Rs. 1.42 lakhs and Rs. (5.90) lakhs for quarter ended 30.09.2024 and half yearly ended 30.09.2024 respectively.

According to the information and explanations given to us by the Management, these interim financial statements/financial information/financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For Rattan Kaur & Associates
Chartered Accountants
FRN: 022513N



(Rattan Kaur)
Partner

M. No. 513530

Place: Chandigarh

Date: 11.11.2024

UDIN: 24513530BKEFKE6953



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30th SEPT 2024						
CIN L24232CH1995PLC015553						
Particulars	CONSOLIDATED					
	Quarter Ended 30.09.2024	Quarter Ended 30.06.2024	Quarter Ended 30.09.2023	Half Year Ended 30.09.2024	Half Year Ended 30.09.2023	Year Ended 31.03.2024
	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
Income from Operations:						
Revenue from operations	1195.68	3316.65	28971.18	4512.32	60005.07	128089.99
Other Income	1300.52	1113.95	739.73	2414.47	1300.31	4536.75
Total Income	2496.20	4430.60	29710.92	6926.80	61305.38	132626.74
EXPENSES:						
a. Cost of Materials Consumed	781.39	213.34	14699.05	994.73	30180.07	59905.88
b. Purchase of stock in Trade	49.85	2517.83	103.77	2567.68	237.62	2533.24
c. (Increase) /decrease in FG,WIP & stock in trade	0.00	0.00	(357.63)	0.00	253.75	3707.27
d. Employee benefit	580.45	608.66	3745.99	1189.11	7647.92	15281.15
e. Finance Costs	41.12	16.88	2113.78	58.00	4152.20	5110.36
f. Depreciation	21.65	24.99	1318.75	46.64	2707.29	5330.28
g. Other expenditure	963.38	950.90	4210.53	1914.28	9086.25	21241.84
TOTAL EXPENSES	2437.83	4332.61	25834.24	6770.44	54265.11	113110.01
Profit(loss) before exceptional Items and Tax	58.36	97.99	3876.68	156.36	7040.27	19516.73
Exceptional Items (Income) /loss	0.00	0.00	0.00	0.00	0.00	(38659.00)
Profit(loss) before Tax (After exceptional Items)	58.36	97.99	3876.68	156.36	7040.27	58175.72
Tax Expenses :-						
Current Tax	18.45	(2.88)	693.07	15.57	1255.54	16211.14
Mat credit Utilisation	0.00	0.00	0.00	0.00	861.52	897.50
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1084.34)
Income Tax Adjustment of Previous Years	0.00	0.00	0.34	0.00	0.34	6.25
Profit/ (Loss) after tax and before share of	39.92	100.87	3183.27	140.78	4922.88	42145.17
Share of profit (loss) in joint venture	1.42	(7.32)	(17.58)	(5.90)	(32.94)	(49.01)
Profit (+)/ Loss (-) for the period from continuing operations	41.34	93.55	3165.70	134.89	4889.93	42096.16
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit / (Loss) for the period after tax & Exceptional Items	41.34	93.55	3165.70	134.89	4889.93	42096.16
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) Items that will be reclassified into P/L A/c	0.00	0.00	37.48	0.00	37.48	34.70
Other Comprehensive Income (Loss) for the period , net of Tax	0.00	0.00	37.48	0.00	37.48	34.70
Total Comprehensive Income for the Period	41.34	93.55	3128.21	134.89	4852.45	42061.46
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						
EPS (of Rs. 10/- each) (Not annualised)						95245.88
Basic	0.07	0.16	5.36	0.23	8.28	71.24
Diluted	0.07	0.16	5.36	0.23	8.28	71.24

FOR IND SWIFT LABORATORIES LIMITED

N.R. Munjal
 N.R. MUNJAL
 CHAIRMAN & MANAGING DIRECTOR

PLACE: CHANDIGARH

DATE: 11/11/2024

Works : Barwala Road, Vill. Bhagwanpur, Near Dera Bassi, Distt. Mohali (Punjab)
 Tel. : + + 91-1762-281072, Telefax : ++91-1762-281073



IND-SWIFT LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED
 Consolidated Statement of Assets & Liabilities :

	Unaudited	Audited
	As At 30.09.2024	As At 31.03.2024
ASSETS		
Non-current assets :		
Property, Plant and Equipment	501.93	536.38
Right of Use - Land	-	-
Capital work-in progress	-	-
Investment property	227.61	229.91
Intangible assets under development	-	-
Financial Assets		
a) Investments		
- In subsidiaries and associates	-	-
- In Others	19,182.07	11,054.48
b) Other Non-current Financial Assets	54.00	48.80
Deferred tax assets (net)	3,184.84	3,185.15
Other non-current assets	36,971.93	35,343.03
TOTAL NON-CURRENT ASSETS	60,122.39	50,397.74
Current Assets		
Inventories	932.89	1,045.77
Financial Assets		
(a) Trade receivables	5,754.81	16,912.19
(b) Cash and cash equivalents	43,845.52	43,192.71
(c) Other current financial Assets	-	-
Other current assets	8,146.36	4,962.23
Total Current Assets	58,679.59	66,112.89
Grand total	1,18,801.98	1,16,510.63
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	5,908.69	5,908.69
(b) Other Equity	95,245.88	87,237.12
Equity attributable to equity holders of the Company	1,01,154.56	93,145.81
(c) Non-Controlling interest	(2.57)	(1.71)
Total Equity	1,01,152.00	93,144.10
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	1,090.21	1,116.26
(b) Lease liabilities	-	-
Provisions	122.64	122.64
Other Non current Liabilities	-	-
Total Non-Current Liabilities	1,212.85	1,238.90
Current liabilities		
Financial Liabilities		
(a) Borrowings	549.40	545.90
(b) Lease liabilities	-	-
(c) Trade payables	4,124.15	9,397.81
(d) Other Financial Liabilities	-	-
(e) Other current liabilities	1,078.50	1,533.32
(f) Provision	10,195.08	10,178.69
Foreign Currency Translation	490.00	471.92
Total Current Liabilities	16,437.14	22,127.63
Grand Total	1,18,801.98	1,16,510.63
	(0.00)	0.00

PLACE: CHANDIGARH
 DATE: 11/11/2024

FOR IND SWIFT LABORATORIES LIMITED

N.R. MUNJAL
 CHAIRMAN & MANAGING DIRECTOR





Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 30.09.2024	Rs in Laacs	
	Half Year ended 30.09.2024	Year ended 31.03.2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and Extra-Ordinary Items	156.36	19516.74
ADJUSTMENTS FOR:		
i) Depreciation	46.64	5,330.27
ii) Provision For doubtful Debt	-	2,476.68
iii) Exchange (profit)/loss	-	(249.79)
iv) Interest on Term loans, NCDS & FD	0.00	4,510.64
v) Interest received	(3,288.35)	(1,837.14)
vi) Loss/(Profit) on sale of fixed assets	-	2,253.20
vii) Income tax adj of previous years	-	(6.25)
viii) Amortisation of Subsidy	-	(1.27)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	-3085.36	31993.08
ADJUSTMENTS FOR:		
i) Trade & Other Receivables	11,207.42	(11,223.76)
ii) Inventories	112.88	3,288.66
iii) Other assets	(4,818.25)	(43,653.47)
iv) Current Liabilities	(5,744.23)	2,598.11
v) Working Capital Borrowing	8.69	685.87
Net Cash flow from operating Activities	(2318.84)	(16311.52)
B. CASH FLOW FROM INVESTING ACTIVITIES		
i) Purchase of fixed Assets Tangible	(9.90)	(4,451.68)
iii) Sale of fixed assets	-	294.65
iv) (Purchase)/ Sale of Investments	(8,133.49)	(8,112.00)
v) Interest Received	3,288.35	1,837.14
Net Cash from investing activities	(4855.04)	(10431.88)
C. CASH FLOW FROM FINANCING ACTIVITIES		
i) Repayment of Term Loans to Banks & Financial Institutions & FD	(29.50)	(3,742.78)
ii) Interest paid on Term Loans & FD	(17.74)	(12,604.55)
iii) Cash flow from Slump sales net of Assets/liab transferred	-	93,520.59
iv) Payments of Income Tax	0.82	(7,281.87)
v) Proceeds from Fully Convertible Warrants	7,873.12	
Net Cash flow from Financing Activities	7,826.70	69,891.38
Net increase in Cash or Cash Equivalents	652.81	43147.98
Opening Cash & Cash Equivalents	43192.71	1819.98
Closing Cash & Cash Equivalents	43845.52	43,192.71
Add; unrealised Gain/(loss) in FCTR	(18.09)	(44.74)
Closing Cash & Cash Equivalents after FCTR	43,827.43	43,147.97

DATE: 11/11/2024
PLACE: CHANDIGARH

FOR IND SWIFT LABORATORIES LIMITED
N.R. Munjal
N.R. MUNJAL
CHAIRMAN & MANAGING DIRECTOR



IND-SWIFT LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Notes: -

1. The standalone and consolidated unaudited financial results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 11th November, , 2024.
2. The standalone and consolidated financial statements for the quarter ended and half year ended 30.09.2024 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
3. Details of amount considered as the exceptional items are as under:

STANDALONE

(Rs. In Lakhs)

Particulars	Quarter ended 30.09.2024	Quarter ended 30.06.2024	Quarter ended 30.09.2023	Half year ended 30.09.2024	Half year ended 30.09.2023	Year ended 31.03.2024*
Exceptional Items	0.00	0.00	0.00	0.00	0.00	38659.00

CONSOLIDATED

(Rs. In Lakhs)


Particulars	Quarter ended 30.09.2024	Quarter ended 30.06.2024	Quarter ended 30.09.2023	Half year ended 30.09.2024	Half year ended 30.09.2023	Year ended 31.03.2024*
Exceptional Items	0.00	0.00	0.00	0.00	0.00	38659.00

* An exceptional gain of INR 386.59 Crores as shown in financial year ended 31st March, 2024 was on account of the slump sale of the API and CRAMS Business of the Company.

4. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company.
5. The consolidated financial results include the financial results of the parent company Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture:
 - a) Ind-Swift Laboratories Inc., USA (Subsidiary)
 - b) Fortune (India) Constructions Limited (Subsidiary)
 - c) Indis Healthcare LLP (Joint Venture)
 - d) MJM Remedies Private Limited (Subsidiary)
 - e) ISLL Middle East LLC-FZ (Subsidiary)

Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'.

6. No adjustment has been made in respect of Deferred Taxes & Current Tax as per IND AS-12, as the same would be provided at the year end.
7. During the quarter under review the Company has not issued any Non-Convertible Debt Securities.





Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



8. During the quarter, the Company has allotted 2,60,00,000 Fully Convertible Warrants, convertible into equal number of shares to promoters and non-promoters on preferential basis at an issue price of Rs. 121/- each.
9. The Company has announced the merger of M/s. Ind Swift Limited with the Company i.e., Ind Swift Laboratories Limited, and the Company has received the observation letters from both the exchanges. A first motion petition has been filed with the Hon'ble National Company Law Tribunal, Chandigarh Bench, for which order has been reserved by the Tribunal.
10. The previous period figures have been re-grouped and re-classified wherever necessary.
11. The Company is exclusively in the Pharmaceutical Business segment.

Place: Chandigarh
Date: 11th November, 2024

For Ind Swift Laboratories Limited


N.R. Munjal
Chairman & Managing Director

